Objective: We hypothesized that long dosing interval antiosteoporosis medications (AOMs), mainly those delivered parenterally, will guarantee higher adherence and persistence, which could help reduce fracture risk. The aim of this research was to evaluate the relationship between different dosing intervals of AOM and the subsequent fracture risk among patients newly initiated AOM therapies. Methods: It is a nationwide population-based cohort study based on Taiwan’s National Health Insurance Research Database. Osteoporosis patients with age C 50 who newly initiated AOM during 2008–2018 (n = 336,229) were included. We categorized AOMs into short dosing intervals (oral AOMs) or long dosing intervals (parenteral AOMs). The adherence and persistence of treatment by medication possession ratio (MPR) and subsequent fracture after treatment for 3 years were measured. Results: Among patients who initiated parenteral AOMs, the percentage of patients with high adherence (MPR C 75%) increased from 33% in 2008 to 69% in 2018. However, among patients who initiated oral AOMs, the percentage of high adherence remained stable (30%) between 2008–2018. The use of parenteral AOMs increased from 1% in 2008 to 62% in 2018. At the same time, the percentage of high adherence of those initiated AOMs significantly increased from 34% in 2008 to 61% in 2018. The risk of subsequent fracture decreased significantly between 2008–2018 after controlling for all potential confounders (hazard ratio = 0.85, 95% CI = 0.81–0.89). Conclusion: AOMs with long dosing intervals not only increased adherence and persistence but also decreased the subsequent fracture risk at a nationwide scale.
Date:
2023-07-21
Relation:
Aging Clinical and Experimental Research. 2023 Jul 21;35:S143.
